B+
Bull case
25%
Probability
Target price
$3.40
+103.6% vs current
IKT
Inhibikase TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.50
-10.2% vs current
B-
Bear case
30%
Probability
Target price
$0.70
-58.1% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+50.9
Score
AI commentary
Sentiment is cautiously constructive but still monitoring-style. The April 7, 2026 first-patient-enrolled update is a real positive because it confirms IMPROVE-PAH is no longer just a design transition story [#8-K-2026-04-07]. Still, the thesis is not yet broadly de-risked: the 10-K shows a very large Phase 3 operational plan, meaningful contracted trial spend, and explicit dependence on future capital flexibility [#10-K-2026-03-26]. Direct PAH comparators now frame the setup more cleanly: Gossamer shows what a real late-stage PAH development peer looks like, Liquidia anchors downstream commercial value, and Keros underscores how quickly PAH trial sentiment can break on mixed data. Given low coverage, negative deterministic return priors, and still-limited forward visibility beyond enrollment start, this remains an early execution watchlist name rather than a high-conviction re-rating today.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystEarly IMPROVE-PAH enrollment cadence updateHigh impact
IKT disclosed first-patient enrollment on April 7, 2026 and said IMPROVE-PAH is actively enrolling across up to ~180 sites; the next operational update matters because it will show whether the global Phase 3 ramp is tracking after the recent Phase 2b-to-Phase 3 pivot [#8-K-2026-04-07] [#10-K-2026-03-26].
2026-11-30eventPhase 3 Part A interim 12-week safety readoutHigh impact
The 10-K ties Series A-1 warrant timing to a public announcement of the Phase 3 Part A interim 12-week safety readout, making this a real financing and sentiment checkpoint rather than a generic trial update [#10-K-2026-03-26].
2027-09-30catalystPhase 3 Part A 24-week PVR efficacy readoutHigh impact
The 10-K also ties Series B-1 warrant timing to a public announcement of the Phase 3 Part A 24-week pulmonary vascular resistance efficacy readout; that makes Part A efficacy the main long-duration value inflection for IKT-001 in PAH [#10-K-2026-03-26] [#8-K-2026-04-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology